Reprogramming cell fates towards novel cancer immunotherapies.
Curr Opin Pharmacol. 2022 Dec;67:102312. doi: 10.1016/j.coph.2022.102312. Epub 2022 Nov 3.
Curr Opin Pharmacol. 2022.
PMID: 36335715
Review.